Started taking arimidex three days ago to combat sides while on my 6th week of test prop @ 500mg/wk and I've been taking .5mg around midday. I was wondering if its better to take this at night rather than midday.
Started taking arimidex three days ago to combat sides while on my 6th week of test prop @ 500mg/wk and I've been taking .5mg around midday. I was wondering if its better to take this at night rather than midday.
I don't think the time of day will make a difference.
actually not that it matters but you should take it right in the mornin' right when you wake up that way you don't forget it.. plus .5 is kinda high what made you decide to go with that dosage?? I like .25 ED or heck even EOD ... anything more than that I feel like I am hindering my gains too much... you need some Estrogen to grow...
Agreed with the comment about taking it first thing that way you dont forget. I do that with my multi V and its hard to forget when its sitting right next to my toothbrush![]()
Thanks for the input guys, I really don't forget to take anything like that... But I was told by my friend and others that I should go with .5mg because my estrogen was too high... I have like no sex drive and erections are weak. This was my 4th dose today at .5mg, should I drop it down to .25mg?
Just curious what sides made you think your est levels were too high? As i have found the sides of arimidex are far worse then a little extra est. As long as i have no gyno i will never take arimidex again on cycle.
Well I noticed that my libido went really far down to the point to where it was hard to get an erection. I also felt really emotional and felt like I could cry about the dumbest shit. When you're trying to lay it down to a girl you're really attracted to and cant keep a boner, you know somethings wrong, especially with all that test.
written by magic32
Firstly, you should know that correlation between when gyno therapy begins and its level of success is a myth. The appropriate treatments work well regardless of the condition's longevity, as clearly illustrated in numerous cases persistent pubertal gyno resolution.* (SEE BELOW)
Secondly, the amount of time necessary to achieve completely reversed or satisfactorily reduced sustained gyno resolution varies greatly, and is based on a several variables such as: condition type and severity (simple fatty, fatty glandular, nodule/bump, or glandular). It is important to note that one should not discontinue therapy as soon as results are seen, because the ratio imbalance (etiological cause) has not yet been wholly corrected within the affected tissue, thereby making recurrence substantially more likely. Conversely, one should continue therapy for a few weeks (observed as a couple of months w/in clinical trials) after satisfactory results have been attained.* (SEE BELOW)
Thirdly, although some have reported success from A-dex therapy, and I’m not refuting the veracity of these claims, they should indeed be considered within the very subjective light in which they’re presented because of the significant body of clinical research to the contrary. In other words, A-dex may impact some individuals, but when combating gyno one should select a better therapeutic agent, which amounts to the appropriate SERM, DHT, or a stronger AI. Furthermore, even better results have been seen with the concurrent and/or sequential administration of two or more of these agents.
Here are a couple of diverse examples of just how IMPOTENT (even at higher doses) A-dex is in gyno therapy:
Quote:
Evaluation of Tamoxifen and Anastrozole in the Prevention of Gynecomastia and Breast Pain Induced by Bicalutamide Monotherapy of Prostate Cancer
F. Boccardo, A. Rubagotti, M. Battaglia, P. Di Tonno, F.P. Selvaggi, G. Conti, G. Comeri, A. Bertaccini, G. Martorana, P. Galassi, F. Zattoni, A. Macchiarella, A. Siragusa, G. Muscas, F. Durand, D. Potenzoni, A. Manganelli, V. Ferraris, F. Montefiore
Journal of Clinical Oncology, Vol 23, No 4 (February 1), 2005: pp. 808-815
http://jco.ascopubs.org/cgi/content/full/23/4/808
Safety and Efficacy of Anastrozole for the Treatment of Pubertal Gynecomastia: A Randomized, Double-Blind, Placebo-Controlled Trial
Paul V. Plourde, Edward O. Reiter, Hann-Chang Jou, Paul E. Desrochers, Stephen D. Rubin, Barry B. Bercu, Frank B. Diamond, Jr. and Philippe F.
Journal of Clinical Oncology, Vol 23, No 4 (February 1), 2005: pp. 808-815
© 2005 American Society of Clinical Oncology.
http://jcem.endojournals.org/cgi/content/full/89/9/4428
-------------------
* THE AFOREMENTIONED PERSISTENT PUBERTAL GYNO RESOLUTION STUDIES & THE SIGNIFICANCE OF TREATMENT DURATION ON SUSTAINED RESULTS:
Quote:
Tamoxifen treatment for pubertal gynecomastia
We evaluated the efficacy of the tamoxifen treatment in 37 patients with pubertal gynecomastia. All had distinct, easily palpable breast swellings with a diameter of over three cm. Pain, tenderness, and swelling associated with gynecomastia were reported by six patients. Eight of the patients were obese. One patient also suffered from varicocele. Pain and size reduction was seen in all patients with tamoxifen treatment. No long-term side effects of tamoxifen were observed. The dose of tamoxifen was increased in three patients due to poor response. Two of the treatment group had recurrence problem at follow-up. We did not need to refer any patient to surgery. Tamoxifen treatment is relatively non-toxic, may be beneficial and we think it should be considered for pubertal gynecomastia.
Derman O, Kanbur NO, Kutluk T.
Section of Adolescent Medicine, Department of Pediatrics,
Hacettepe University Faculty of Medicine, 06100 Ankara-Turkey.
Quote:
Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate.
Four boys with persistent pubertal gynecomastia were given intramuscular dihydrotestosterone heptanoate (DHT-hp) at 2 to 4-week intervals for 16 weeks. By the end of treatment, breast size in all four boys had decreased 67% to 78%. Initial plasma levels of gonadotropins, estradiol, testosterone, and dihydrotestosterone (DHT) were normal. Mean plasma DHT concentration rose with the injections of DHT-hp, and remained elevated throughout the treatment period. Estradiol, LH, FSH, and testosterone decreased during treatment, as did 24-hour urinary LH and FSH. No regrowth of breast tissue was observed 6 to 15 months after treatment, although hormone concentrations had returned to near pretreatment values by 2 months after the last injection. DHT-hp has potential to be an effective medical therapy for persistent pubertal gynecomastia.
Eberle AJ; Sparrow JT; Keenan BS
J Pediatr 1986 Jul;109(1):144-9.
Quote:
Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia.
OBJECTIVES: To assess the efficacy of the anti-estrogens tamoxifen and raloxifen in the medical management of persistent pubertal gynecomastia. STUDY DESIGN: Retrospective chart review of 38 consecutive patients with persistent pubertal gynecomastia who presented to a pediatric endocrinology clinic. Patients received reassurance alone or a 3- to 9-month course of an estrogen receptor modifier (tamoxifen or raloxifene). RESULTS: Mean (SD) age of treated subjects was 14.6 (1.5) years with gynecomastia duration of 28.3 (16.4) months. Mean reduction in breast nodule diameter was 2.1 cm (95% CI 1.7, 2.7, P <.0001) after treatment with tamoxifen and 2.5 cm (95% CI 1.7, 3.3, P <.0001) with raloxifene. Some improvement was seen in 86% of patients receiving tamoxifen and in 91% receiving raloxifene, but a greater proportion had a significant decrease (>50%) with raloxifene (86%) than tamoxifen (41%). No side effects were seen in any patients. CONCLUSION: Inhibition of estrogen receptor action in the breast appears to be safe and effective in reducing persistent pubertal gynecomastia, with a better response to raloxifene than to tamoxifen. Further study is required to determine that this is truly a treatment effect.
Lawrence SE; Faught KA; Vethamuthu J; Lawson ML
J Pediatr. 2004 Jul;145(1):71-6.
what makes you think arimidex works against gyno?[/QUOTE]
I know arimidex isnt a gyno therapy. I wasnt thinking it thru wen i posted. What i meant to say was that the sides from estrogen such as water retention are minor compared to the sides i get from armidex at .25mg eod or .5mg x2 a week.
I know arimidex isnt a gyno therapy. I wasnt thinking it thru wen i posted. What i meant to say was that the sides from estrogen such as water retention are minor compared to the sides i get from armidex at .25mg eod or .5mg x2 a week.[/QUOTE]
gotcha, that i definitely agree with(well i don't know about he adex sides but i know some people that don't like adex for that reason)
yea.. i was doing .5 eod and my sex drive was taking an ass kicking.. iv dropped it down to .25 eod, might even go down to .2
the reason i took arimidex was the remove water weight i had gained while on a test cycle. It worked very well at this, however the loss of sex drive and an extreme increase in joint pain made it not worth taking anymore. Also i did think it hindered gains however have no proof of this.
Ya, my sex drive still hasn't improved drastically from what it was before (today was 4th dose of arimidex @ .5mg) I was going to put it down to .25mg after sex drive started coming back, but I'm kinda lost at what to do at this point because my drive still hasn't improved that much.
My mistake i must have read that wrong i thought those sides were from the arimidex as i get loss of sex drive from the adex not the test.
oh lol, ya i can see why you would be confused, shouldn't have loss of drive on test, but i guess i'm one of the unfortunate ones.
There are currently 1 users browsing this thread. (0 members and 1 guests)